Zhengzhou

Running trials

• Not yet recruiting

  A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

  NCT07816237· Phase 3· Bisirna Therapeutics (Suzhou) Co., Ltd.· Source

  Contact: Charlene Si